Se connecter

Bibliographies thématiques / Multiple myeloma Chemotherapy / Articles de revues

Pour voir les autres types de publications sur ce sujet consultez le lien suivant : Multiple myeloma Chemotherapy.

Articles de revues sur le sujet « Multiple myeloma Chemotherapy »

Auteur : Grafiati

Publié le 4 juin 2021

Mis à jour le 30 janvier 2023

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les 50 meilleurs articles de revues pour votre recherche sur le sujet « Multiple myeloma Chemotherapy ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Parcourez les articles de revues sur diverses disciplines et organisez correctement votre bibliographie.

1

Durie, Brian G. M. "Chemotherapy of multiple myeloma." Baillière's Clinical Haematology 4, no. 1 (January 1991): 181–95. http://dx.doi.org/10.1016/s0950-3536(05)80290-2.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Kogan, Michael, and Adnan H. Siddiqui. "Intracranial Multiple Myeloma After Chemotherapy." Archives of Clinical and Medical Case Reports 01, no. 02 (2017): 42–44. http://dx.doi.org/10.26502/acmcr.9655008.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Lokhorst, H. M., O. J. A. Th Meuwissen, E. J. E. G. Bast, and A. W. Dekker. "VAD chemotherapy for refractory multiple myeloma." British Journal of Haematology 71, no. 1 (January 1989): 25–30. http://dx.doi.org/10.1111/j.1365-2141.1989.tb06269.x.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

Peest, D., H. J. Schmoll, I. Schedel, S. Glück, K. Schumacher, and H. Deicher. "VBAMDex chemotherapy in advanced multiple myeloma*." European Journal of Haematology 40, no. 3 (April 24, 2009): 245–49. http://dx.doi.org/10.1111/j.1600-0609.1988.tb00831.x.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

Terrovitis, John V., Charis Matsouka, Athanassios Anagnostopoulos, Maria I. Anastasiou-Nana, and Athanassios Meletios Dimopoulos. "Hemophagocytic Lymphohistiocytosis After Chemotherapy for Multiple Myeloma." Clinical Lymphoma 5, no. 3 (December 2004): 194–96. http://dx.doi.org/10.3816/clm.2004.n.026.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Alexanian, Raymond, Bart Barlogie, and Gerard Ventura. "Chemotherapy for resistant and relapsing multiple myeloma." European Journal of Haematology 43, S51 (April 24, 2009): 140–44. http://dx.doi.org/10.1111/j.1600-0609.1989.tb01507.x.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

7

Vidarsson, Brynjar, Svanhvit Olafsdottir, and Sigrun Reykdal. "VASP Chemotherapy in Patients with Multiple Myeloma." Blood 106, no. 11 (November 16, 2005): 5189. http://dx.doi.org/10.1182/blood.v106.11.5189.5189.

Texte intégral

Résumé :

Abstract Introduction: Multiple myeloma (MM) is a malignant disorder of plasma cells resistant to chemotherapy. Various chemotherapy protocols are available for patients with MM, including VAD (vincristine, adriamycin, prednisolon) and MP (melphalan, prednisolon). These therapies aim to slow disease progression and/or prepare the patient for stem cell transplantation (SCT), the standard of care for MM patients younger than 70. An additional regimen, VASP, consisting of etoposide 50mg/m2 IV on day 1 and 100mg/m2 PO on days 2–4, adriamycin 25mg/m2 IV on day 1, cyclophosphamide 500mg/m2 IV on day

Styles APA, Harvard, Vancouver, ISO, etc.

8

Minařík, Jiří, and Sabina Ševčíková. "Immunomodulatory Agents for Multiple Myeloma." Cancers 14, no. 23 (November 23, 2022): 5759. http://dx.doi.org/10.3390/cancers14235759.

Texte intégral

Résumé :

The treatment of multiple myeloma (MM) has undergone a significant paradigm shift in the last 20 years, from conventional chemotherapy to more tumor-specific treatments, based on the interference with pathogenesis of the malignant clone as well as the bone microenvironment [...]

Styles APA, Harvard, Vancouver, ISO, etc.

9

Katagiri, Daisuke, Eisei Noiri, and Fumihiko Hinoshita. "Multiple Myeloma and Kidney Disease." Scientific World Journal 2013 (2013): 1–9. http://dx.doi.org/10.1155/2013/487285.

Texte intégral

Résumé :

Multiple myeloma (MM) has a high incidence rate in the elderly. Responsiveness to treatments differs considerably among patients because of high heterogeneity of MM. Chronic kidney disease (CKD) is a common clinical feature in MM patients, and treatment-related mortality and morbidity are higher in MM patients with CKD than in patients with normal renal function. Recent advances in diagnostic tests, chemotherapy agents, and dialysis techniques are providing clinicians with novel approaches for the management of MM patients with CKD. Once reversible factors, such as hypercalcemia, have been cor

Styles APA, Harvard, Vancouver, ISO, etc.

10

Bensinger, William I. "Hematopoietic Cell Transplantation for Multiple Myeloma." Cancer Control 5, no. 3 (May 1998): 235–42. http://dx.doi.org/10.1177/107327489800500304.

Texte intégral

Résumé :

Background Multiple myeloma (MM) is a malignant plasma cell disorder with a median survival of three years. Despite the development of numerous conventional chemotherapy regimens and interferons, there has been little progress in improving the survival of patients with MM. Very high-dose chemoradiotherapy and autologous or allogeneic hematopoetic stem cell transplantation (HSCT) can result in high complete remission rates, even in patients with advanced disease. Methods A prospective, randomized study has shown that autologous HSCT results in superior response rates, progression-free survival,

Styles APA, Harvard, Vancouver, ISO, etc.

11

&NA;. "High-dose chemotherapy + stem cells for multiple myeloma." Inpharma Weekly &NA;, no. 1387 (May 2003): 13. http://dx.doi.org/10.2165/00128413-200313870-00036.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

12

Rohatgi, Nidhi, Xianglin L. Du, Ann L. Coker, Lemuel A. Moye, Michael Wang, and Shenying Fang. "Chemotherapy and Survival for Patients With Multiple Myeloma." American Journal of Clinical Oncology 30, no. 5 (October 2007): 540–48. http://dx.doi.org/10.1097/coc.0b013e3180592a30.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

13

Anderson, H., JH Scarffe, M. Ranson, R. Young, GS Wieringa, GR Morgenstern, L. Fitzsimmons, and D. Ryder. "VAD chemotherapy as remission induction for multiple myeloma." British Journal of Cancer 71, no. 2 (February 1995): 326–30. http://dx.doi.org/10.1038/bjc.1995.65.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

14

Puri, Sonam, Jitesh Joshi, Olga Derman, Noah Kornblum, Amit Verma, Ira Braunschweig, and Ramakrishna Battini. "Ocular Complications of Bortezomib Therapy in Multiple Myeloma." Blood 124, no. 21 (December 6, 2014): 5743. http://dx.doi.org/10.1182/blood.v124.21.5743.5743.

Texte intégral

Résumé :

Abstract Introduction: Bortezomib (Velcade¨; V), a proteasome inhibitor, is currently FDA (Food and Drug Administration) approved for the treatment of multiple myeloma (MM) and relapsed mantle cell lymphoma. Common side effects reported with its use include thrombocytopenia, fatigue, peripheral neuropathy and neutropenia. Ocular complications associated with bortezomib are less well described. We describe 6 patients with multiple myeloma who developed meibomitis, multiple chalazions and blepharitis after treatment with bortezomib containing regimens, resulting in delay and in some cases termin

Styles APA, Harvard, Vancouver, ISO, etc.

15

Kristinsson, Sigurdur Yngvi. "Thrombosis in Multiple Myeloma." Hematology 2010, no. 1 (December 4, 2010): 437–44. http://dx.doi.org/10.1182/asheducation-2010.1.437.

Texte intégral

Résumé :

Abstract Patients with multiple myeloma (MM) are at an increased risk of venous and arterial thrombosis. The pathogenesis remains unclear, but probably involves several factors such as activation of procoagulant factors, acquired activated protein C resistance, and inflammation. In addition to general risk factors for venous thromboembolism, such as older age, immobility, surgery, and inherited thrombophilia, there are some MM-specific and treatment-related factors that contribute to the increased risk. The risk for venous thromboembolism is high when patients are treated with thalidomide or l

Styles APA, Harvard, Vancouver, ISO, etc.

16

Chng, Wee Joo, Lee Gong Lau, Noorainun Yusof, and Benjamin M. F. Mow. "Targeted Therapy in Multiple Myeloma." Cancer Control 12, no. 2 (April 2005): 91–104. http://dx.doi.org/10.1177/107327480501200204.

Texte intégral

Résumé :

Background: Multiple myeloma (MM) is an incurable malignancy. Recent insights into its biology has allowed the use of novel therapies targeting not only the deregulated intracellular signaling in MM cells but also its interaction with the bone marrow microenvironment that confers drug resistance, growth, and survival advantage to the malignant cells. Methods: We review and summarize the recent advances in our knowledge of myeloma biology as well as the mechanism of action and clinical efficacy for novel therapeutic agents in clinical trials. Results: Several novel therapeutic agents are curren

Styles APA, Harvard, Vancouver, ISO, etc.

17

Lonial, Sagar. "Relapsed Multiple Myeloma." Hematology 2010, no. 1 (December 4, 2010): 303–9. http://dx.doi.org/10.1182/asheducation-2010.1.303.

Texte intégral

Résumé :

Abstract Advances in treatment options for patients with multiple myeloma have made a significant impact on the overall survival of patients and have helped achieve levels of response and duration of remission previously not achievable with standard chemotherapy-based approaches. These improvements are due, in large part, to the development of the novel agents thalidomide, bortezomib, and lenalidomide, each of which has substantial single-agent activity. In addition, a large number of second-generation agents are also in clinical development, such that the repertoire of available treatment opt

Styles APA, Harvard, Vancouver, ISO, etc.

18

Li, Juan, Junhe Li, Shaokai Luo, and Yin Zhao. "Expression of TRAIL Receptors on the Multiple Myeloma Cells." Blood 104, no. 11 (November 16, 2004): 4868. http://dx.doi.org/10.1182/blood.v104.11.4868.4868.

Texte intégral

Résumé :

Abstract Objective To study the different expression of death receptors and decoy receptors on mononuclear cells from patients with multiple myeloma and myeloma cell line KM3 and compare the different expression of TRAIL receptors after chemotherapy or exposure to doxorubicin, to explore the mechanisms by which TRAIL selectively kills tumor cells. Methods Semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) and flow cytometry was used to investigate the expression of four receptors on mononuclear cells in 23 multiple myeloma patients and myeloma cell line KM3 and 15 contr

Styles APA, Harvard, Vancouver, ISO, etc.

19

Luca, Dragos C., and Imad Y. Almanaseer. "Simultaneous Presentation of Multiple Myeloma and Acute Monocytic Leukemia." Archives of Pathology & Laboratory Medicine 127, no. 11 (November 1, 2003): 1506–8. http://dx.doi.org/10.5858/2003-127-1506-spomma.

Texte intégral

Résumé :

Abstract Acute leukemia frequently has been described as a late complication of chemotherapy with alkylating agents in patients treated for multiple myeloma. However, the simultaneous occurrence of multiple myeloma and acute leukemia in the same patient, without previous exposure to chemotherapy, is a rare association. We describe a case of concomitant involvement by multiple myeloma and acute monocytic leukemia. To our knowledge, only 9 such cases have been reported in the literature to date. We discuss the criteria used in diagnosing the 2 separate diseases and the possible mechanisms respon

Styles APA, Harvard, Vancouver, ISO, etc.

20

Tu, Yong-sheng, Jin He, Huan Liu, Richard Eric Davis, Robert Z. Orlowski, Joshua E. Allen, and Jing Yang. "ONC201 Overcomes Chemotherapy Resistance By Upregulation of Bim in Multiple Myeloma." Blood 128, no. 22 (December 2, 2016): 4476. http://dx.doi.org/10.1182/blood.v128.22.4476.4476.

Texte intégral

Résumé :

Abstract In multiple myeloma, disease relapse and drug resistance occurs in the majority of myeloma patients after standard treatment despite recent improvements offered by new therapies. Therefore, there is an urgent need for new drugs that can overcome drug resistance and prolong patient survival after failure of standard therapies. ONC201, the founding member of a novel class of anti-tumor agents called impridones, has selective preclinical efficacy against a variety of tumor types. It is currently in phase I and phase II clinical trials for patients with advanced solid tumors and hematolog

Styles APA, Harvard, Vancouver, ISO, etc.

21

Mohamed, Muhajir, and Karen Dun. "Complex hypodiploid acute myeloid leukaemia secondary to chemotherapy for hyperdiploid multiple myeloma." International Journal of Hematology 100, no. 1 (May 13, 2014): 3–6. http://dx.doi.org/10.1007/s12185-014-1594-y.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

22

Huff, Carol Ann, and William Matsui. "Multiple Myeloma Cancer Stem Cells." Journal of Clinical Oncology 26, no. 17 (June 10, 2008): 2895–900. http://dx.doi.org/10.1200/jco.2007.15.8428.

Texte intégral

Résumé :

Multiple myeloma is characterized by the clonal expansion of neoplastic plasma cells within the bone marrow, elevated serum immunoglobulin, and osteolytic bone disease. The disease is highly responsive to a wide variety of anticancer treatments including conventional cytotoxic chemotherapy, corticosteroids, radiation therapy, and a growing number of agents with novel mechanisms of action. However, few if any patients are cured with these modalities and relapse remains a critical issue. A better understanding of clonogenic multiple myleoma cells is essential to ultimately improving long-term ou

Styles APA, Harvard, Vancouver, ISO, etc.

23

Todaro, Juliana, Patrícia Weinschenker Bollmann, Amit Nussbacher, Luis Fernando Aranha Camargo, Bento Fortunato Cardoso dos Santos, Daniel Alvarenga, Laercio Alberto Rosemberg, David Costa de Souza Le Bihan, Cláudio Henrique Fischer, and Auro del Giglio. "Multiple myeloma complicated with pseudomonas endocartiditis." Einstein (São Paulo) 10, no. 4 (December 2012): 498–501. http://dx.doi.org/10.1590/s1679-45082012000400017.

Texte intégral

Résumé :

Patients diagnosed with multiple myeloma are more susceptible to infections which are the major causes of morbidity and mortality associated to this disease. The main infectious agents involved are Gram-positive bacteria. However, after chemotherapy an increase in the incidence of Gram-negative strains is observed. These bacteria are also responsible for most cases of urinary tract infections. Here is reported a rare case in a 73-year-old man with multiple myeloma who developed endocarditis due to pseudomonas.

Styles APA, Harvard, Vancouver, ISO, etc.

24

Chandran, Rekha, Miklos Simon, and Stephen E. Spurgeon. "Concurrent Presentation of Hodgkin Lymphoma and Multiple Myeloma." Case Reports in Hematology 2013 (2013): 1–3. http://dx.doi.org/10.1155/2013/398769.

Texte intégral

Résumé :

The simultaneous presentation of the Hodgkin lymphoma and multiple myeloma in the absence of prior chemotherapy or radiation is very rare. Here, we discuss a 72-year-old patient who initially presented with generalized pruritis. Workup led to a diagnosis of multiple myeloma which progressed and required treatment. As part of his pretreatment workup, an MRI was performed to evaluate skeletal lesions. This revealed diffuse and bulky adenopathy which was confirmed by PET. A biopsy of an axillary node was consistent with the nodular sclerosing type Hodgkin lymphoma. He was treated with adriamycin,

Styles APA, Harvard, Vancouver, ISO, etc.

25

Berneman, Zwi N., An-Sofie Verstraete, Alain Gadisseur, Ann Van de Velde, and Wilfried A. Schroyens. "The Survival of Multiple Myeloma Patients: A Single Institution Study." Blood 104, no. 11 (November 16, 2004): 5223. http://dx.doi.org/10.1182/blood.v104.11.5223.5223.

Texte intégral

Résumé :

Abstract Background: For a long time, multiple myeloma has been a disease with a poor outcome. High dose (melphalan) chemotherapy followed by autologous stem cell transplantation has been reported to improve the overall and progression-free survival of these patients. Objective: To determine the survival of multiple myeloma patients treated with conventional chemotherapy and compare it with that of patients treated with high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation. Design/Methods: 83 myeloma patients treated at a single institution were included in t

Styles APA, Harvard, Vancouver, ISO, etc.

26

Kaneko, Haruo, Ken Shikoshi, Shuichi Annou, Masashi Takada, Motoharu Kato, Setsuro Moro, Mikio Yamauchi, and Tatsuo Shirai. "VCAP Combination Chemotherapy for Multiple Myeloma in the Aged." Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 28, no. 4 (1991): 504–8. http://dx.doi.org/10.3143/geriatrics.28.504.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

27

Johnstone, Megan, Delaney Vinaixa, Marcello Turi, Eugenio Morelli, Kenneth Carl Anderson, and Annamaria Gulla. "Promises and Challenges of Immunogenic Chemotherapy in Multiple Myeloma." Cells 11, no. 16 (August 14, 2022): 2519. http://dx.doi.org/10.3390/cells11162519.

Texte intégral

Résumé :

Immunological tolerance of myeloma cells represents a critical obstacle in achieving long-term disease-free survival for multiple myeloma (MM) patients. Over the past two decades, remarkable preclinical efforts to understand MM biology have led to the clinical approval of several targeted and immunotherapeutic agents. Among them, it is now clear that chemotherapy can also make cancer cells “visible” to the immune system and thus reactivate anti-tumor immunity. This knowledge represents an important resource in the treatment paradigm of MM, whereas immune dysfunction constitutes a clear obstacl

Styles APA, Harvard, Vancouver, ISO, etc.

28

Ii, Frederick Richards, Morton Coleman, M. Robert Cooper, and W. Perry Ballard. "Multiple Myeloma—Complete Remission with High Dose Melphalan Chemotherapy." Cancer Investigation 3, no. 1 (January 1985): 15–21. http://dx.doi.org/10.3109/07357908509040604.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

29

Wright, A., S. Elkins, J. Files, C. Bigelow, V. Herrin, and M. Sample. "THROMBOEMBOLISM IN MULTIPLE MYELOMA PATIENTS RECEIVING THALIDOMIDE COMBINATION CHEMOTHERAPY." Journal of Investigative Medicine 55, no. 1 (January 2007): S302. http://dx.doi.org/10.1097/00042871-200701010-00839.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

30

Ucci, G., A. Riccardi, P. Dörmer, M. Danova, and R. Luoni. "Early Plasma Cell Recruitment In Multiple Myeloma Following Chemotherapy." Cell Proliferation 21, no. 6 (November 1988): 405–9. http://dx.doi.org/10.1111/j.1365-2184.1988.tb00800.x.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

31

Palva, I. P., P. Ahrenberg, A. Almquist, K. Ala-Harja, J. Apajalahti, H. Hallman, A. Hänninen, et al. "Aggressive combination chemotherapy in multiple myeloma. A multicentre trial." Scandinavian Journal of Haematology 35, no. 2 (April 24, 2009): 205–9. http://dx.doi.org/10.1111/j.1600-0609.1985.tb01574.x.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

32

Palva, I. P. "Combination chemotherapy MOCCA in resistant and relapsing multiple myeloma." European Journal of Haematology 48, no. 1 (April 24, 2009): 37–40. http://dx.doi.org/10.1111/j.1600-0609.1992.tb01791.x.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

33

Fassas, Athanasios B. T., Trey Spencer, Raman Desikan, Maurizio Zangari, Elias Anaissie, Bart Barlogie, and Guido Tricot. "Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients." British Journal of Haematology 119, no. 1 (October 2002): 164–68. http://dx.doi.org/10.1046/j.1365-2141.2002.03772.x.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

34

SWAN, GEORGE W. "Optimal Control Applications in the Chemotherapy of Multiple Myeloma." Mathematical Medicine and Biology 2, no. 3 (1985): 139–60. http://dx.doi.org/10.1093/imammb/2.3.139.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

35

Zhan, Fenghuang, Wen Zhou, Maurizio Zangari, Hongwei Xu, and Guido J. Tricot. "ALDH1 Activity Identifies Chemotherapy-Resistant Multiple Myeloma Stem Cells." Blood 118, no. 21 (November 18, 2011): 990. http://dx.doi.org/10.1182/blood.v118.21.990.990.

Texte intégral

Résumé :

Abstract Abstract 990 Background: Cancer stem cells are a chemotherapy-resistant subpopulation capable of self-renewal and of regenerating bulk tumor, thereby causing relapse and ultimately patient's death. Aldehyde dehydrogenase 1 (ALDH1) has been found to be a reliable marker for cancer stem cells in many human malignancies. The purpose of this study is to investigate the stem cell–related function and clinical significance of ALDH1 in myeloma. Materials and Methods: 9 myeloma (MM) cell lines (XG6, KMS12B, ARP1, 8226, U266, H929, JJN3, OPM2, 5T33) were assessed for ALDH1 activity using the A

Styles APA, Harvard, Vancouver, ISO, etc.

36

Becker, Pamela S. "Genetic Predisposition for Chemotherapy-Induced Neuropathy in Multiple Myeloma." Journal of Clinical Oncology 29, no. 7 (March 1, 2011): 783–86. http://dx.doi.org/10.1200/jco.2010.33.4771.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

37

Song, Yan, Ning Hu, Xiaowei Song, and Juhong Yang. "Hsa_Circ_0007841 Enhances Multiple Myeloma Chemotherapy Resistance Through Upregulating ABCG2." Technology in Cancer Research & Treatment 19 (January 1, 2020): 153303382092837. http://dx.doi.org/10.1177/1533033820928371.

Texte intégral

Résumé :

The current researches have reported that circular RNA is an important regulatory factor in the progression of various human disease. However, the function and mechanism of most circular RNAs remain unknown in cancers including multiple myeloma. Our study has confirmed that hsa_circ_0007841 is up regulated in U266 doxorubicin resistant cells (U266R) and 8226 doxorubicin resistant cells (8226R) compared to U266 parent cells (U266P) and 8226 parent cells (8226P). Silence of hsa_circ_0007841 in U266R and 8226R could reduce the half-maximal inhibitory concentration which indicated reduction in che

Styles APA, Harvard, Vancouver, ISO, etc.

38

Kryukov, E. V., V. N. Troyan, O. A. Rukavitsyn, S. V. Kozyrev, I. G. Daragan-Sushchov, V. P. Pop, S. A. Alekseev, and E. R. Sapelnikova. "Densitometry as a monitoring method in the treatment of patients with multiple myeloma." Medical Visualization, no. 5 (October 28, 2018): 106–13. http://dx.doi.org/10.24835/1607-0763-2018-5-106-113.

Texte intégral

Résumé :

The article is devoted to the study of the problem of the analysis of the degree of osteoporosis based on the results of dual-energy x-ray absorptiometry in multiple myeloma during treatment. The change in bone mineral density in patients with multiple myeloma treated with standard chemotherapy and high-dose chemotherapy with autotransplantation of hematopoietic stem cells is considered. The X-ray densitometry method can serve as an objective criterion for evaluating the effectiveness of the treatment in patients with multiple myeloma.

Styles APA, Harvard, Vancouver, ISO, etc.

39

Sinclair, David, Adel Resouly, and Anne Spedding. "Stridor: unusual presentation of multiple myeloma." Journal of Laryngology & Otology 117, no. 10 (October 2003): 829–31. http://dx.doi.org/10.1258/002221503770716313.

Texte intégral

Résumé :

We present a patient with multiple myeloma whose only presenting symptom was stridor caused by a subglottic stenosis. Biopsy suggested the presence of amyloid which prompted immunological investigations that showed hypogammaglobulinaemia and the presence of Bence Jones proteinuria at 0.93 g/24 hours. Further investigation demonstrated a 15 per cent plasma cell infiltrate into the bone marrow and a lytic lesion in the mid-shaft of the right femur. Chemotherapy and localized radiotherapy were commenced. This is a most unusual presentation of multiple myeloma and shows that immunoglobulin profile

Styles APA, Harvard, Vancouver, ISO, etc.

40

Israelyan, E. R., C. S. Golovataya, O. K. Bondarenko, A. V. Nayda, and A. K. Pudeeva. "Onset of multiple myeloma with rheumatic polymyalgia." Medical Herald of the South of Russia 10, no. 4 (December 26, 2019): 98–104. http://dx.doi.org/10.21886/2219-8075-2019-10-4-98-104.

Texte intégral

Résumé :

A clinical observation of a patient presented with a typical clinic of rheumatic polymyalgia (RPM), which was a manifestation of myeloma. The relationship between rheumatic polymyalgia and giant cell arteritis (GCA) is well known, but association of RPM with lymphoproliferative diseases is rarely reported. In this case there was a clinical improvement in the patient’s condition aft er chemotherapy treatment.

Styles APA, Harvard, Vancouver, ISO, etc.

41

Palva, I. P., K. Ala-Harja, A. Almqvist, E. Elonen, H. Hallman, A. Hänninen, M. Ilvonen, et al. "Corticosteroid is not beneficial in multiple-drug combination chemotherapy for multiple myeloma." European Journal of Haematology 51, no. 2 (April 24, 2009): 98–101. http://dx.doi.org/10.1111/j.1600-0609.1993.tb01600.x.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

42

Salmon, S. E., J. J. Crowley, T. M. Grogan, P. Finley, R. P. Pugh, and B. Barlogie. "Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study." Journal of Clinical Oncology 12, no. 11 (November 1994): 2405–14. http://dx.doi.org/10.1200/jco.1994.12.11.2405.

Texte intégral

Résumé :

PURPOSE Standard therapy for multiple myeloma consists of cytotoxic chemotherapy plus glucocorticoids. Interferon (IFN) alfa maintenance is reported to prolong chemotherapy-induced remissions and survival. This study evaluates induction chemotherapy, glucocorticoids, and interferon maintenance in myeloma. PATIENTS AND METHODS Five hundred twenty-two previously untreated myeloma patients were randomized to three chemotherapy regimens with differing glucocorticoid intensities. Patients who achieved remission were randomized to receive IFN or observation until relapse. Patients who failed to resp

Styles APA, Harvard, Vancouver, ISO, etc.

43

Coss, Alan, Chen Zhou, Michael F. Byrne, and Alan A. Weiss. "Relapse of Multiple Myeloma Presenting with Biliary Obstruction." Canadian Journal of Gastroenterology 24, no. 4 (2010): 237–38. http://dx.doi.org/10.1155/2010/593859.

Texte intégral

Résumé :

Pancreatic infiltration is a rare feature of multiple myeloma. A case of a 74-year-old man presenting with symptomatic biliary obstruction two years after the original diagnosis of myeloma is described. Confirmation of pancreatic infiltration with myeloma cells was performed by endoscopic ultrasound-guided fine-needle aspiration. Biliary stenting was performed at endoscopic retrograde cholangiopancreatography. Resolution of the pancreatic mass and the associated biliary stricture was observed after radiation and chemotherapy.

Styles APA, Harvard, Vancouver, ISO, etc.

44

Sawicki, C. P., S. A. Climans, C. C. Hsia, and J. A. Fraser. "Progressive multifocal leukoencephalopathy during ixazomib-based chemotherapy." Current Oncology 25, no. 1 (February 28, 2018): 99. http://dx.doi.org/10.3747/co.25.3674.

Texte intégral

Résumé :

Progressive multifocal leukoencephalopathy (pml) is a rare demyelinating disease of the central nervous system that most often affects immunocompromised individuals. It is caused by the reactivation of the John Cunningham virus (jcv), which is found in latent form in the majority of adults. We describe a 59-year-old man with multiple myeloma who developed severe neurological deficits during treatment with ixazomib-based chemotherapy. A diagnosis of pml was established with gadolinium-enhanced magnetic resonance imaging (mri) and by detection of jcv in the cerebrospinal fluid. Despite cessation

Styles APA, Harvard, Vancouver, ISO, etc.

45

Haegelen, Claire, Laurent Riffaud, Marc Bernard, Beatrice Carsin-Nicol, and Xavier Morandi. "Dural plasmacytoma revealing multiple myeloma." Journal of Neurosurgery 104, no. 4 (April 2006): 608–10. http://dx.doi.org/10.3171/jns.2006.104.4.608.

Texte intégral

Résumé :

✓The authors describe the case of a 72-year-old woman with dural plasmacytoma revealing an immunoglobulin (Ig) G-kappa multiple myeloma (MM). She presented with headaches and left hemiparesis. Magnetic resonance imaging demonstrated a right frontal extraaxial lesion arising from the dura mater, and biological studies revealed hypercalcemia, hyperproteinemia, and a serum gamma globulin peak. A diagnosis of IgG-kappa MM was based on microscopic examination and immunohistochemical analysis of the dural plasmacytoma as well as on signs of systemic myeloma after surgery. The patient died 3 years af

Styles APA, Harvard, Vancouver, ISO, etc.

46

Sampat, Parth J., Maneesh Bisen, Nimisha Srivastava, Suman Rao, and Teresa Gentile. "Accidental Ixazomib Overdose in a Patient With Multiple Myeloma." Journal of Investigative Medicine High Impact Case Reports 9 (January 2021): 232470962110132. http://dx.doi.org/10.1177/23247096211013230.

Texte intégral

Résumé :

Multiple myeloma is the second most common hematological malignancy. Ixazomib is the first oral proteasome inhibitor approved in the United States for the management of multiple myeloma who have received at least one prior treatment. The availability of oral chemotherapeutic agents for the management of multiple myeloma has made it easier for patients who do not have to come to the hospital for chemotherapy infusions. However, many barriers are associated with oral chemotherapy, and one of them is a misinterpretation of instruction which can have deleterious effects. In this case report, we pr

Styles APA, Harvard, Vancouver, ISO, etc.

47

Rathnakumar, Geeta, Kinjalka Ghosh, Nikhil Choudhary, Narendra Kamble, and Nitin Inamdar. "Study of prognostic factors in multiple myeloma." International Journal of Advances in Medicine 8, no. 11 (October 26, 2021): 1694. http://dx.doi.org/10.18203/2349-3933.ijam20214131.

Texte intégral

Résumé :

Background: Multiple myeloma (MM) is cancer of the plasma cell characterized by interpatient heterogeneity, in most of the cases it is incurable. It is the second most common hematological malignancy. Overall survival of patients has significantly increased recently. Lot of research is going on for prognostic factors, which can predict disease and response to therapy. During the past decades, biomarkers: M protein and β2 microglobulin have shaped the knowledge about MM. This study was undertaken to evaluate the role of prognostic factors in newly diagnosed and few follow up patients of MM befo

Styles APA, Harvard, Vancouver, ISO, etc.

48

Quesada, JR, R. Alexanian, M. Hawkins, B. Barlogie, E. Borden, L. Itri, and JU Gutterman. "Treatment of multiple myeloma with recombinant alpha-interferon." Blood 67, no. 2 (February 1, 1986): 275–78. http://dx.doi.org/10.1182/blood.v67.2.275.275.

Texte intégral

Résumé :

Abstract Thirty-two patients with multiple myeloma were treated with recombinant alpha-interferon clone A (rIFN alpha A) daily by intramuscular injection with an initial dose of 12 X 10(6) U/m2. Of 27 patients evaluable for response, tumor responses were obtained in seven of 14 previously untreated patients (50%) and two of 13 who had relapsed or failed prior chemotherapy (15%). In all patients who had tumor response, there was restoration from subnormal levels of serum immunoglobulins, an effect infrequently observed with chemotherapy. The median duration of tumor responses exceeded 14 months

Styles APA, Harvard, Vancouver, ISO, etc.

49

Quesada, JR, R. Alexanian, M. Hawkins, B. Barlogie, E. Borden, L. Itri, and JU Gutterman. "Treatment of multiple myeloma with recombinant alpha-interferon." Blood 67, no. 2 (February 1, 1986): 275–78. http://dx.doi.org/10.1182/blood.v67.2.275.bloodjournal672275.

Texte intégral

Résumé :

Thirty-two patients with multiple myeloma were treated with recombinant alpha-interferon clone A (rIFN alpha A) daily by intramuscular injection with an initial dose of 12 X 10(6) U/m2. Of 27 patients evaluable for response, tumor responses were obtained in seven of 14 previously untreated patients (50%) and two of 13 who had relapsed or failed prior chemotherapy (15%). In all patients who had tumor response, there was restoration from subnormal levels of serum immunoglobulins, an effect infrequently observed with chemotherapy. The median duration of tumor responses exceeded 14 months (range,

Styles APA, Harvard, Vancouver, ISO, etc.

50

Ostrovskyi, V. L., I. M. Skrypnyk, G. S. Maslova, O. A. Shaposhnyk, and L. I. Yakymyshyna. "PECULIARITIES OF MYOCARDIAL BIOELECTRIC ACTIVITY IN PATIENTS WITH PROGRESSIVE MYLTIPLE MYELOMA RECEIVING BORTEZOMIB-CONTAINING CHEMOTHERAPY SCHEMES." Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії 22, no. 3-4 (November 29, 2022): 80–84. http://dx.doi.org/10.31718/2077-1096.22.3.4.80.

Texte intégral

Résumé :

Introduction. New approaches to the oncohematology management that also include multiple myeloma treatment, makes higher level of hematological remission and improve survival rates. But novel cytostatic drugs have higher incidence of cardiotoxicity. According to the modern multiple myeloma management guidelines, patients, who have no indications for bone morrow transplantation, should be treated by VRd chemotherapy scheme as a first line therapy. The VRd scheme includes: bortezomib, lenalidomid and dexamethasone. Both early cytostatic-induced cardiovascular toxicity risk factor indicatio

Styles APA, Harvard, Vancouver, ISO, etc.

Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!